Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Precision risk-based screening might maximize benefit and minimize harm

Population-based mammographic screening is widely accepted as an intervention to reduce overall mortality from breast cancer, but at the cost of morbidity due to false positives and substantial overdiagnosis and overtreatment of ultra-low-risk disease, as well as personal and health-economic burdens. Recent data from a modelling study strengthen the rationale for personalized, risk-based screening approaches, now being tested in multiple clinical trials.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Pashayan, N. et al. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. JAMA Oncol. (2018).

    Article  PubMed  Google Scholar 

  2. Klompenhouwer, E. G. et al. Re-attendance at biennial screening mammography following a repeated false positive recall. Breast Cancer Res. Treat. 145, 429–437 (2014).

    Article  Google Scholar 

  3. Dabbous, F. M. et al. Impact of a false-positive screening mammogram on subsequent screening behavior and stage at breast cancer diagnosis. 26, 397–403 (2017).

  4. Siu, A. L., U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 164, 279–296 (2016).

    Article  Google Scholar 

  5. Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017).

    Article  CAS  Google Scholar 

  6. Vachon, C. M. et al. The contributions of breast density and common genetic variation to breast cancer risk. J. Natl Cancer Inst. 107, 397–400 (2015).

    Article  Google Scholar 

  7. Esserman, L. J. et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA Oncol. 3, 1503–1510 (2017).

    Article  Google Scholar 

  8. Esserman, L. J. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer 3, 34 (2017).

    Article  Google Scholar 

  9. Shieh, Y. et al. Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial. J. Natl Cancer Inst. 109, djw290 (2017).

    Article  Google Scholar 

Download references


We thank J. Matthews, University of California, San Francisco, for his excellent editorial assistance.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Laura J. Esserman.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links





Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esserman, L.J., LaCroix, A.Z. Precision risk-based screening might maximize benefit and minimize harm. Nat Rev Clin Oncol 15, 661–662 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer